Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Yun Shin Chun(The University of Texas MD Anderson Cancer Center), John P. Hoffman(Fox Chase Cancer Center), James C. Watson(Vanderbilt University), Barbara Burtness(Yale University), Oleh Haluszka(Fox Chase Cancer Center), Igor Astsaturov(Fox Chase Cancer Center), Steven J. Cohen(Abington Memorial Hospital), Jeffrey L. Tokar(Fox Chase Cancer Center), Barton N. Milestone(Fox Chase Cancer Center), Crystal S. Denlinger(Fox Chase Cancer Center), Paul F. Engstrom(Fox Chase Cancer Center), Michael J. Hall(Fox Chase Cancer Center)
Cited by 132
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin
|Journal of Clinical Oncology|2000|746
Colon Cancer
|Journal of the National Comprehensive Cancer Network|2009|684